Home › Companies › Humacyte, Inc. › 2025-2026

Humacyte, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Humacyte, Inc.’s Form 8-K, filed 2026-06-09 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
128Asset managers
1,021Fund votes
2026-06-09Meeting date

Proxy season: 2025-2026

Explore Humacyte, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Humacyte, Inc.

These tallies are Humacyte, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-09 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Humacyte, Inc. — official shareholder meeting results, meeting held 2026-06-09
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: John P. Bamforth	48,332,651	--	--	13,968,428	65,173,007	Majority: yes
Elect Director: Keith Anthony Jones	52,871,152	--	--	9,429,927	65,173,007	Majority: yes
Elect Director: Kathleen Sebelius	52,765,738	--	--	9,535,341	65,173,007	Majority: yes
Proposal 2: Approval of Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as described in the executive compensation section of the proxy statement	40,100,324	19,493,367	2,707,388	--	65,173,007	Majority: yes
Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The appointment of Pricewaterhouse Coopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified	125,187,135	1,654,285	632,666	--	--	Majority: yes
Proposal 5: Approval of an Amendment to the Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock	102,313,282	23,088,322	2,072,482	--	--	Majority: yes

Source: Humacyte, Inc., Form 8-K, filed with the SEC on 2026-06-09 — read the filing on EDGAR.

How asset managers voted at the Humacyte, Inc. 2025-2026 meeting

Each item below shows how the 128 asset managers that disclosed a Humacyte, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Humacyte, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on an advisory basis, of the compensation paid to Humacyte, Inc.'s named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%AGAINST 33%

FOR: 40,100,324AGAINST: 19,493,367

Humacyte, Inc.’s own tally for this item (“Proposal 2: Approval of Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as described in the executive compensation se”): 40,100,324 for, 19,493,367 against, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 222,019,108 outstanding shares: 18% for, 9% against (27% of the company cast a for/against vote).

The 128 asset managers below cast 41% of the shares they voted on this item FOR (5,486,393 for, 7,898,812 against).

FOR 41%AGAINST 59%

FOR: 5,486,393 (41.0%)AGAINST: 7,898,812 (59.0%)ABSTAIN: 3 (0.0%)

Largest asset managers voting on “Approval, on an advisory basis, of the compensation paid to Humacyte, Inc.'s named executive officers.” at Humacyte, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
ANTIPODES PARTNERS Ltd	0	5,657,136	0	Against
BlackRock	1,597,701	0	0	For
State Street	1,088,907	7,055	0	For
Vanguard	699,788	5,764	3	For
AQR	0	667,045	0	Against
Northern Trust	0	628,763	0	Against
Roundview Capital LLC	500,000	0	0	For
Woodline Partners LP	391,478	0	0	For
MELLON INVESTMENTS Corp	344,890	0	0	For
Charles Schwab	0	240,834	0	Against
AllianceBernstein	0	145,560	0	Against
Equitable	22,786	97,430	0	Against
Lincoln Financial	97,200	0	0	For
Nuveen	96,192	0	0	For
Fidelity	71,089	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	69,635	0	0	For
Bridge Builder Trust	67,878	0	0	For
STIFEL NICOLAUS & CO INC \MO\	0	61,808	0	Against
BANK OF AMERICA NA	57,711	0	0	For
Goldman Sachs	56,967	0	0	For
Voya	0	48,490	0	Against
LETKO, BROSSEAU & ASSOCIATES INC	45,950	0	0	For
T. Rowe Price	0	31,372	0	Against
Jain Global LLC	31,073	0	0	For
SEI	29,982	0	0	For

Showing the 25 largest of 128 asset managers. See all 128 in the interactive database.

2. Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to Humacyte, Inc.'s named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

0.1% fund support · no official result

ONE YEAR 53.1%1 YEAR 46.5%

The 123 asset managers below cast 0.1% of the shares they voted on this item FOR (1 for, 28,263 against).

FOR: 1 (0.0%)AGAINST: 28,263 (0.4%)ONE YEAR: 3,893,675 (53.1%)1 YEAR: 3,411,039 (46.5%)2 YEARS: 1,523 (0.0%)3 YEARS: 900 (0.0%)1-YEAR: 320 (0.0%)1.0: 25 (0.0%)2.0: 6 (0.0%)3.0: 1 (0.0%)

Largest asset managers voting on “Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to ” at Humacyte, Inc., 2025-2026
Asset manager	Against	Vote
BlackRock	0	1 Year
State Street	0	One Year
Vanguard	0	One Year
AQR	0	One Year
Northern Trust	0	1 Year
Roundview Capital LLC	0	1 Year
MELLON INVESTMENTS Corp	0	One Year
Charles Schwab	0	1 Year
AllianceBernstein	0	One Year
Equitable	0	One Year
Lincoln Financial	0	One Year
Nuveen	0	One Year
Fidelity	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	One Year
Bridge Builder Trust	0	1 Year
STIFEL NICOLAUS & CO INC \MO\	0	One Year
BANK OF AMERICA NA	0	1 Year
Goldman Sachs	0	One Year
Voya	0	One Year
LETKO, BROSSEAU & ASSOCIATES INC	0	1 Year
T. Rowe Price	0	One Year
Jain Global LLC	0	One Year
SEI	0	1 Year
Rhumbline	28,263	Against
Invesco	0	One Year

Showing the 25 largest of 123 asset managers. See all 123 in the interactive database.

3. APPROVAL OF AN AMENDMENT TO HUMACYTE, INC.'S SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE TOTAL NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 350,000,000 SHARES TO 550,000,000 SHARES.

CAPITAL STRUCTUREMajority of the votes cast: yes

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%

FOR: 102,313,282AGAINST: 23,088,322

Humacyte, Inc.’s own tally for this item (“Proposal 5: Approval of an Amendment to the Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock”): 102,313,282 for, 23,088,322 against, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 222,019,108 outstanding shares: 46.1% for, 10% against (56% of the company cast a for/against vote).

The 34 asset managers below cast 99.9% of the shares they voted on this item FOR (2,183,130 for, 8 against).

FOR 99.9%

FOR: 2,183,130 (100.0%)AGAINST: 8 (0.0%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO HUMACYTE, INC.'S SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMEN” at Humacyte, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BlackRock	858,608	0	0	For
Vanguard	688,510	8	1	For
Charles Schwab	120,392	0	0	For
Equitable	120,216	0	0	For
Lincoln Financial	97,200	0	0	For
Bridge Builder Trust	67,878	0	0	For
Fidelity	61,642	0	0	For
Voya	24,245	0	0	For
DWS	23,802	0	0	For
Global X	17,362	0	0	For
SEI	14,991	0	0	For
AIG/SunAmerica	14,275	0	0	For
Calvert	12,796	0	0	For
Venerable Variable Insurance Trust	10,381	0	0	For
ProShares	8,776	0	0	For
Pacific Life	7,227	0	0	For
State Street	6,623	0	0	For
Principal	6,131	0	0	For
Nationwide	5,008	0	0	For
Morgan Stanley	3,350	0	0	For
PENN SERIES FUNDS INC	3,100	0	0	For
TIAA	2,451	0	0	For
Goldman Sachs	1,937	0	0	For
John Hancock	1,887	0	0	For
Invesco	1,323	0	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

4. Election of three Class II directors to serve until the 2029 annual meeting of stockholders: John P. Bamforth

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%

FOR: 48,332,651WITHHELD: 13,968,428

Humacyte, Inc.’s own tally for this item (“Elect Director: John P. Bamforth”): 48,332,651 for, 13,968,428 withheld, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 222,019,108 outstanding shares: 22% for, 6% withheld (28% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (4,460 for, 0 against).

ABSTAIN 99.7%

FOR: 4,460 (0.2%)ABSTAIN: 2,178,679 (99.8%)

Largest asset managers voting on “Election of three Class II directors to serve until the 2029 annual meeting of stockholders: John P. Bamforth” at Humacyte, Inc., 2025-2026
Asset manager	For	Abstain	Vote
BlackRock	0	858,608	Abstain
Vanguard	1,200	687,319	Abstain
Charles Schwab	0	120,392	Abstain
Equitable	0	120,216	Abstain
Lincoln Financial	0	97,200	Abstain
Bridge Builder Trust	0	67,878	Abstain
Fidelity	0	61,642	Abstain
Voya	0	24,245	Abstain
DWS	0	23,802	Abstain
Global X	0	17,362	Abstain
SEI	0	14,991	Abstain
AIG/SunAmerica	0	14,275	Abstain
Calvert	0	12,796	Abstain
Venerable Variable Insurance Trust	0	10,381	Abstain
ProShares	0	8,776	Abstain
Pacific Life	0	7,227	Abstain
State Street	0	6,623	Abstain
Principal	0	6,131	Abstain
Nationwide	0	5,008	Abstain
Morgan Stanley	0	3,350	Abstain
PENN SERIES FUNDS INC	0	3,100	Abstain
TIAA	0	2,451	Abstain
Goldman Sachs	1,937	0	For
John Hancock	0	1,887	Abstain
Invesco	1,323	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

5. Election of three Class II directors to serve until the 2029 annual meeting of stockholders: Kathleen Sebelius

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 52,765,738WITHHELD: 9,535,341

Humacyte, Inc.’s own tally for this item (“Elect Director: Kathleen Sebelius”): 52,765,738 for, 9,535,341 withheld, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 222,019,108 outstanding shares: 24% for, 4% withheld (28% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (1,985,859 for, 0 against).

FOR 91%9%

FOR: 1,985,859 (91.0%)ABSTAIN: 197,280 (9.0%)

Largest asset managers voting on “Election of three Class II directors to serve until the 2029 annual meeting of stockholders: Kathleen Sebelius” at Humacyte, Inc., 2025-2026
Asset manager	For	Abstain	Vote
BlackRock	858,608	0	For
Vanguard	686,448	2,071	For
Charles Schwab	120,392	0	For
Equitable	22,786	97,430	Abstain
Lincoln Financial	97,200	0	For
Bridge Builder Trust	67,878	0	For
Fidelity	61,642	0	For
Voya	0	24,245	Abstain
DWS	0	23,802	Abstain
Global X	17,362	0	For
SEI	14,991	0	For
AIG/SunAmerica	0	14,275	Abstain
Calvert	0	12,796	Abstain
Venerable Variable Insurance Trust	10,381	0	For
ProShares	0	8,776	Abstain
Pacific Life	7,227	0	For
State Street	6,623	0	For
Principal	0	6,131	Abstain
Nationwide	5,008	0	For
Morgan Stanley	0	3,350	Abstain
PENN SERIES FUNDS INC	3,100	0	For
TIAA	2,451	0	For
Goldman Sachs	1,937	0	For
John Hancock	0	1,887	Abstain
Invesco	1,323	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

6. Election of three Class II directors to serve until the 2029 annual meeting of stockholders: Keith Anthony Jones

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD 15%

FOR: 52,871,152WITHHELD: 9,429,927

Humacyte, Inc.’s own tally for this item (“Elect Director: Keith Anthony Jones”): 52,871,152 for, 9,429,927 withheld, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 222,019,108 outstanding shares: 24% for, 4% withheld (28% of the company cast a for/withheld vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (2,025,861 for, 0 against).

FOR 93%7%

FOR: 2,025,861 (92.8%)ABSTAIN: 157,278 (7.2%)

Largest asset managers voting on “Election of three Class II directors to serve until the 2029 annual meeting of stockholders: Keith Anthony Jon” at Humacyte, Inc., 2025-2026
Asset manager	For	Abstain	Vote
BlackRock	858,608	0	For
Vanguard	688,511	8	For
Charles Schwab	120,392	0	For
Equitable	22,786	97,430	Abstain
Lincoln Financial	97,200	0	For
Bridge Builder Trust	67,878	0	For
Fidelity	61,642	0	For
Voya	24,245	0	For
DWS	0	23,802	Abstain
Global X	17,362	0	For
SEI	14,991	0	For
AIG/SunAmerica	0	14,275	Abstain
Calvert	12,796	0	For
Venerable Variable Insurance Trust	10,381	0	For
ProShares	0	8,776	Abstain
Pacific Life	7,227	0	For
State Street	6,623	0	For
Principal	0	6,131	Abstain
Nationwide	5,008	0	For
Morgan Stanley	0	3,350	Abstain
PENN SERIES FUNDS INC	3,100	0	For
TIAA	2,451	0	For
Goldman Sachs	1,937	0	For
John Hancock	0	1,887	Abstain
Invesco	1,323	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

7. Ratification of the selection of PricewaterhouseCoopers LLP by the Board of Directors as Humacyte, Inc.'s independent registered public accounting firm for the year ending December 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 125,187,135AGAINST: 1,654,285

Humacyte, Inc.’s own tally for this item (“Proposal 4: Ratification of the Selection of Independent Registered Public Accounting Firm The appointment of Pricewaterhouse Coopers LLP as the Company's independent registered public accounting firm for the fiscal year”): 125,187,135 for, 1,654,285 against, per its Form 8-K filed 2026-06-09 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 222,019,108 outstanding shares: 56% for, 0.8% against (57% of the company cast a for/against vote).

The 34 asset managers below cast 100% of the shares they voted on this item FOR (2,183,138 for, 0 against).

FOR 100%

FOR: 2,183,138 (100.0%)

Largest asset managers voting on “Ratification of the selection of PricewaterhouseCoopers LLP by the Board of Directors as Humacyte, Inc.'s inde” at Humacyte, Inc., 2025-2026
Asset manager	For	Vote
BlackRock	858,608	For
Vanguard	688,518	For
Charles Schwab	120,392	For
Equitable	120,216	For
Lincoln Financial	97,200	For
Bridge Builder Trust	67,878	For
Fidelity	61,642	For
Voya	24,245	For
DWS	23,802	For
Global X	17,362	For
SEI	14,991	For
AIG/SunAmerica	14,275	For
Calvert	12,796	For
Venerable Variable Insurance Trust	10,381	For
ProShares	8,776	For
Pacific Life	7,227	For
State Street	6,623	For
Principal	6,131	For
Nationwide	5,008	For
Morgan Stanley	3,350	For
PENN SERIES FUNDS INC	3,100	For
TIAA	2,451	For
Goldman Sachs	1,937	For
John Hancock	1,887	For
Invesco	1,323	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

8. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 99.9%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (5,657,136 for, 0 against).

FOR: 5,657,136 (100.0%)ONE YEAR: 326 (0.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Humacyte, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
ANTIPODES PARTNERS Ltd	5,657,136	0	0	0	For
TD Waterhouse Canada Inc.	0	0	0	0	One Year

Largest Humacyte, Inc. shareholders voting in 2025-2026

Ranked by the number of Humacyte, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 222,019,108 shares outstanding at the time of that meeting.

Top Humacyte, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	ANTIPODES PARTNERS Ltd	2.55%
2	BlackRock	0.72%
3	State Street	0.49%
4	Vanguard	0.32%
5	AQR	0.30%
6	Northern Trust	0.28%
7	Roundview Capital LLC	0.23%
8	Woodline Partners LP	0.18%
9	MELLON INVESTMENTS Corp	0.16%
10	Charles Schwab	0.11%

Reported Humacyte, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Humacyte, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Fresenius Medical Care Holdings, Inc.	6.13%	13D
Davidson Kempner Arbitrage, Equities & Relative Value LP	5.65%	13G
BlackRock	5.55%	13F
Vanguard Group	3.79%	13F
Brady W. Dougan	2.06%	DEF14A
Laura E. Niklason	2.06%	DEF14A
Geode Capital	1.65%	13F
State Street	1.37%	13F
Morgan Stanley	1.13%	13F
AQR Capital	0.87%	13F

Percentages above are of 222,019,108 shares outstanding, as reported by Humacyte, Inc. on its Form 10-Q dated 2026-05-11 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Humacyte, Inc.’s 10-Q dated 2026-05-11. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Humacyte, Inc.'s shareholder meeting held 2026-06-09, in the 2025-2026 proxy season, 128 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,021 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation paid to Humacyte, Inc.'s named executive… — FOR was 67% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Humacyte, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-09.

Humacyte, Inc. proxy season coverage: 2025-2026 (this page).